This website is intended for healthcare professionals only.
A CLINICAL PERSPECTIVE ON PREMEDICATION
AND THERAPEUTIC DRUG MONITORING (TDM)
IN THE ALL AIEOP-BFM TRIALS
Prof Carmelo Rizzari Pediatric Hematology-Oncology Unit, MBBM Foundation, ASST-Monza University of Milano-Bicocca, Monza, Italy
This webinar presented a clinical perspective on premedication and therapeutic drug monitoring (TDM) in the ALL AIEOP-BFM trials. It discussed why TDM is necessary to help identify inadequate asparaginase activity, to help design more appropriate asparaginase treatment schedules, and to maintain treatment outcomes. It also covers TDM feasibility in clinical practice and the potential challenges.
Key points covered
This webinar presented a clinical perspective on premedication and therapeutic drug monitoring (TDM)
in the ALL AIEOP-BFM trials.
Perspectives on premedication and TDM from the ALL AIEOP-BFM trials
The importance of TDM in ensuring patients receive maximum benefit from asparaginase-containing regimens
Prof Carmelo Rizzari covers cases from his own experience where TDM has helped in decision making to ensure patients receive the most appropriate treatment
Webinar Replay
Featured Speakers
Professor Carmelo Rizzari
Prof Carmelo Rizzari is Professor of Pediatrics at the University of Milano-Bicocca, Italy. His main research interests are in the field of pediatric leukemias with a special focus on both traditional and innovative chemotherapy agents. He is currently head of the Pediatric Hematology-Oncology Unit in Monza (MBBM Foundation, ASSTMonza, University of Milano-Bicocca, Italy), which is one of the largest centers for the diagnosis and treatment of hematological malignancies in Italy. Prof Rizzari is Chairman of the AIEOP (Associazione Italiana di Ematologia ed Oncologia Pediatrica) Acute Lymphoblastic Leukemia (ALL) Committee and the President of SIOP Europe (European Society of Paediatric Oncology).
